FMS - Fresenius Medical Care AG & Co. KGaA

NYSE - NYSE Delayed Price. Currency in USD

Fresenius Medical Care AG & Co. KGaA

Else-Kröner Strasse 1
Bad Homburg 61352
Germany
49 6172 609 0
http://www.freseniusmedicalcare.com

SectorHealthcare
IndustryMedical Care
Full Time Employees118,308

Key Executives

NameTitlePayExercisedYear Born
Mr. Robert Maurice Powell Jr.Chairman of the Management Board & CEO of Fresenius Medical Care Mgmt AG4.17MN/A1955
Mr. Michael BrosnanCFO & Member of the Management Board at Fresenius Medical Care Mgmt AG2.77MN/A1955
Mr. Kent WanzekCEO of Global Mfg, Quality & Supply and Member of Management Board - Fresenius Medical Care Mgmt AG2.01MN/A1959
Dr. Olaf SchermeierCEO of Global R&D and Member of the Management Board - Fresenius Medical Care Mgmt AG1.64MN/A1972
Mr. Harry de WitCEO of APAC & Member of Management Board - Fresenius Medical Care Mgmt AG1.59MN/A1962
Amounts are as of December 31, 2017 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Fresenius Medical Care AG & Co. KGaA, a kidney dialysis company, provides dialysis care and related services, and other health care services in Germany, the United States, and internationally. It offers dialysis treatment and related laboratory and diagnostic services through a network of outpatient dialysis clinics; materials, training, and patient support services comprising clinical monitoring, follow-up assistance, and arranging for delivery of the supplies to the patient's residence; and dialysis services under contract to hospitals in the United States for the hospitalized end-stage renal disease (ESRD) patients and for patients suffering from acute kidney failure. The company also develops, manufactures, and distributes dialysis products, including hemodialysis machines, peritoneal cyclers, dialyzers, peritoneal solutions, hemodialysis concentrates, solutions and granulates, bloodlines, renal pharmaceuticals, and water treatment systems for the treatment of ESRD; and non-dialysis products, such as acute cardiopulmonary and apheresis products. In addition, it develops, acquires, and in-licenses renal pharmaceuticals; offers renal medications and supplies to patients at homes or to dialysis clinics; and provides vascular, cardiovascular, endovascular specialty, hospitalist, emergency, intensivist, medical cost management, ambulatory surgery center, health plan, urgent care, physician nephrology and cardiology, and ambulant treatment services. The company sells its products to clinics, hospitals, and specialized treatment clinics directly, as well as through local sales forces, independent distributors, dealers, and sales agents. As of December 31, 2018, it operated 3,928 outpatient dialysis clinics in approximately 150 countries. Fresenius Medical Care AG & Co. KGaA was incorporated in 1996 and is headquartered in Bad Homburg, Germany.

Corporate Governance

Fresenius Medical Care AG & Co. KGaA’s ISS Governance QualityScore as of April 1, 2019 is 6. The pillar scores are Audit: 1; Board: 8; Shareholder Rights: 1; Compensation: 4.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.